Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Blog - Page 76

Blog

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19
COVID-19 | Life Science History

AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19

On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…

Read More AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19Continue

University of Missouri researchers identified mutations of Delta, Delta Plus variants
COVID-19 | Life Science History

University of Missouri researchers identified mutations of Delta, Delta Plus variants

On Sept. 28, 2021, the University of Missouri researcher Kamlendra Singh led a team that analyzed protein sequences…

Read More University of Missouri researchers identified mutations of Delta, Delta Plus variantsContinue

Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMA
Life Science History

Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMA

On Sept. 28, 2021, Quest Diagnostics reported that one in two (50.5%) American children under six years of…

Read More Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMAContinue

Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine
Biotechnology | COVID-19 | Life Science History | Therapeutics | Vaccine

Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine

On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…

Read More Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 VaccineContinue

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to
COVID-19 | FDA | Life Science History

Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of age

On Sept. 28, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…

Read More Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of ageContinue

Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITM
COVID-19 | Life Science History

Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITM

On Sept. 27, 2021, RELIEF THERAPEUTICS reported its U.S. collaboration partner, NRx Pharmaceuticals, had announced top line data…

Read More Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITMContinue

Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults
COVID-19 | Life Science History

Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults

On Sept. 27, 2021, Pfizer announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for…

Read More Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adultsContinue

Pfizer announced Study of mRNA-based next generation flu vaccine program
Biotechnology | Infectious Disease | Influenza | Vaccine

Pfizer announced Study of mRNA-based next generation flu vaccine program

On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…

Read More Pfizer announced Study of mRNA-based next generation flu vaccine programContinue

Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine

On Sept. 24, 2021, Moderna announced a supply agreement with the government of Peru for 20 million doses…

Read More Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccineContinue

USDA confirmed COVID-19 in Ferret in Florida
Agriculture | Biotechnology | COVID-19 | Infectious Disease | USDA | Vaccine | Veterinary

USDA confirmed COVID-19 in Ferret in Florida

On Sept. 24, 2021, the U.S. Department of Agriculture’s (USDA) announced confirmation of SARS-CoV-2 in a ferret in…

Read More USDA confirmed COVID-19 in Ferret in FloridaContinue

Twist Bioscience single domain antibody TB202-3 showed potent binding to multiple strains of SARS-CoV-2
COVID-19 | Life Science History

Twist Bioscience single domain antibody TB202-3 showed potent binding to multiple strains of SARS-CoV-2

On Sept. 23, 2021, Twist Bioscience reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to…

Read More Twist Bioscience single domain antibody TB202-3 showed potent binding to multiple strains of SARS-CoV-2Continue

Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine | WHO

Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine

On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…

Read More Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccineContinue

Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
Biotechnology | Infectious Disease | Influenza | Vaccine

Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases

On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…

Read More Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious DiseasesContinue

Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
COVID-19 | FDA | Life Science History

Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster

On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…

Read More Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine boosterContinue

Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics

On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…

Read More Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeuticsContinue

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease

OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver

On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…

Read More OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA WaiverContinue

Winners of 2022 Breakthrough Prizes In Life Sciences announced
Biotechnology | COVID-19 | Genomics | HIV | Vaccine

Winners of 2022 Breakthrough Prizes In Life Sciences announced

On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…

Read More Winners of 2022 Breakthrough Prizes In Life Sciences announcedContinue

Clover Biopharmaceuticals’s vaccine using Dynavax’s CpG 1018 adjuvant met primary and secondary efficacy endpoints
COVID-19 | Life Science History | Vaccine

Clover Biopharmaceuticals’s vaccine using Dynavax’s CpG 1018 adjuvant met primary and secondary efficacy endpoints

On Sept. 22, 2021, Dynavax Technologies announced that Clover Biopharmaceuticals reported positive data for their protein-based COVID-19 vaccine…

Read More Clover Biopharmaceuticals’s vaccine using Dynavax’s CpG 1018 adjuvant met primary and secondary efficacy endpointsContinue

Veklury (Remdesivir) significantly reduced risk of hospitalization in high-risk patients with COVID-19
Biotechnology | COVID-19 | Disease | Therapeutics

Veklury (Remdesivir) significantly reduced risk of hospitalization in high-risk patients with COVID-19

On Sept. 22, 2021, Gilead Sciences announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to…

Read More Veklury (Remdesivir) significantly reduced risk of hospitalization in high-risk patients with COVID-19Continue

Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countries
Biotechnology | COVID-19 | Therapeutics | Vaccine

Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countries

On Sept. 22, 2021, Pfizer and BioNTech announced plans to expand their agreement with the U.S. government by…

Read More Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countriesContinue

INOVIO received regulatory authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate in Mexico
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO received regulatory authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate in Mexico

On Sept. 22, 2021, Inovio Pharmaceuticals announced that it had received authorization from COFEPRIS, the national health regulatory…

Read More INOVIO received regulatory authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate in MexicoContinue

The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis C
Life Science History | Nanotechnology

The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis C

On Sept. 21, 2021, the Medicines Patent Pool (MPP) announced that it had signed a licence agreement with…

Read More The Medicines Patent Pool secured its first licence for malaria, tuberculosis and hepatitis CContinue

Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER study
COVID-19 | Life Science History

Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER study

On Sept. 20, 2021, Eiger BioPharmaceuticals announced announced that Peginterferon Lambda (Lambda) will be added to the ongoing,…

Read More Eiger BioPharma announced interim analysis of dosing of Peginterferon Lambda in phase 3 TOGETHER studyContinue

Pfizer and BioNTech announced positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years
COVID-19 | Life Science History | Vaccine

Pfizer and BioNTech announced positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years

On Sept. 20, 2021, Pfizer and BioNTech announced results from a Phase 2/3 trial showing a favorable safety…

Read More Pfizer and BioNTech announced positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 yearsContinue

University of Oxford and Oracle Cloud System helped researchers identify COVID-19 variants faster
COVID-19 | Non-Profit Research

University of Oxford and Oracle Cloud System helped researchers identify COVID-19 variants faster

On Sept. 20, 2021, the University of Oxford and Oracle’s Global Pathogen Analysis System announced that it was…

Read More University of Oxford and Oracle Cloud System helped researchers identify COVID-19 variants fasterContinue

Great cats tested presumptive positive for COVID-19 at the Smithsonian’s National Zoo
COVID-19 | Life Science History

Great cats tested presumptive positive for COVID-19 at the Smithsonian’s National Zoo

On Sept. 17, 2021, the lions and tigers at the Smithsonian’s National Zoo were reported testing presumptive positive…

Read More Great cats tested presumptive positive for COVID-19 at the Smithsonian’s National ZooContinue

Zoo Atlanta reported nine western lowland gorillas tested positive for COVID-19
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | Veterinary

Zoo Atlanta reported nine western lowland gorillas tested positive for COVID-19

On Sept. 17, 2021, Zoo Atlanta reported that of the 20 gorillas at the Zoo, 18 showed clinical…

Read More Zoo Atlanta reported nine western lowland gorillas tested positive for COVID-19Continue

US Department of Defense awarded $647 million in contracts for over-the-counter COVID-19 test kits
Biotechnology | COVID-19 | Diagnostics | Medical Device

US Department of Defense awarded $647 million in contracts for over-the-counter COVID-19 test kits

On Sept. 17, 2021, the U.S. Department of Defense in coordination with the Department of Health and Human…

Read More US Department of Defense awarded $647 million in contracts for over-the-counter COVID-19 test kitsContinue

CDC to invest $2.1 billion to protect patients and healthcare workers from COVID-19 and future infectious diseases
CDC | COVID-19 | Life Science History

CDC to invest $2.1 billion to protect patients and healthcare workers from COVID-19 and future infectious diseases

On Sept. 17, 2021, the Centers for Disease Control and Prevention (CDC) announced a $2.1 billion investment to…

Read More CDC to invest $2.1 billion to protect patients and healthcare workers from COVID-19 and future infectious diseasesContinue

The COVID-19 pandemic has caused the biggest decrease in life expectancy since World War II
COVID-19 | Life Science History

The COVID-19 pandemic has caused the biggest decrease in life expectancy since World War II

On Sept. 17, 2021, Oxfordメs Leverhulme Centre for Demographic Science reported the COVID-19 pandemic triggered life expectancy losses…

Read More The COVID-19 pandemic has caused the biggest decrease in life expectancy since World War IIContinue

Page navigation

Previous PagePrevious 1 … 74 75 76 77 78 … 346 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search